Global Immunotherapy Drugs Market Size Study, by Type, by Application, by Route of Administration, by End User and Regional Forecasts 2022-2032

Description

Global immunotherapy drugs market is valued at approximately USD 247.44 billion in 2023 and is projected to grow at a healthy CAGR of 15.3% over the forecast period 2024-2032. Immunotherapy drugs represent a paradigm shift in the treatment of various diseases, most notably cancer. These drugs harness and enhance the body's immune system to identify and eliminate cancer cells more effectively, offering a powerful alternative to traditional cancer treatments. The market's growth is underpinned by significant technological advancements in antibody engineering, which have enabled the development of more targeted and effective therapeutic agents. This innovation is crucial in addressing the increasing demand for personalized medicines and targeted therapies, particularly in oncology, where precision treatment is becoming the standard of care.

The demand for immunotherapy drugs is also driven by the rising incidence of cancer and other chronic diseases, alongside the growing preference for therapies that offer a better safety profile and fewer side effects compared to conventional treatments. However, the development and commercialization of these drugs are challenged by the stringent regulatory approval processes that require substantial financial and time investments. Smaller companies, in particular, may find these requirements to be a significant barrier to market entry.

Despite these challenges, opportunities abound in the market, particularly through strategic collaborations among pharmaceutical companies, contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and academic institutions. These collaborations are critical in accelerating research and development, reducing costs, and enhancing market penetration. As such, the market is expected to witness robust growth, driven by the continuous innovation and expansion of immunotherapy applications across different therapeutic areas.

The North American region is expected to dominate the global immunotherapy drugs market, accounting for the largest share due to the region's advanced healthcare infrastructure, significant investment in research and development, and the high prevalence of cancer and other chronic diseases. The market in this region is further bolstered by the increasing approval and adoption of immunotherapy drugs, alongside strong governmental support for healthcare innovation. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period fueled by rising incidence of cancer, increasing healthcare expenditure, and growing awareness about advanced treatment options. The region's large population, coupled with the growing adoption of immunotherapy as a preferred treatment, is fueling market growth. Additionally, government initiatives supporting healthcare infrastructure development and research are contributing to the market's expansion.

Major market players included in this report are:

Merck & Co., Inc. (US)
Johnson & Johnson Services, Inc. (US)
F. Hoffman-La Roche Ltd. (Switzerland)
Pfizer Inc. (US)
AstraZeneca (UK)
Novartis AG (Switzerland)
Amgen Inc. (US)
Gilead Sciences, Inc. (UK)
Bristol-Myers Squibb Company (US)
Eli Lilly and Company (US)
Sanofi (France)
Takeda Pharmaceutical Company Limited (Japan)
Teva Pharmaceutical Industries Ltd (Israel)
GSK PLC (US)
Abbvie Inc. (US)

The detailed segments and sub-segment of the market are explained below:

By Type

Antibody Drugs
Inhibitor Drugs
Interferons and Interleukins
Cancer Vaccines
Other Types

By Application

Cancer
Autoimmune and Inflammatory Diseases
Hematology
Osteology
Neurology
Other Applications

By Route of Administration

Intravenous
Subcutaneous
Other Routes of Administration

By End User

Hospitals
Long-Term Care Facilities
Other End Users

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional-level analysis for each market segment.
Detailed analysis of the geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand-side and supply-side analysis of the market.

Chapter 1. Global Immunotherapy Drugs Market Executive Summary

1.1. Global Immunotherapy Drugs Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Type
- 1.3.2. By Application
- 1.3.3. By Route of Administration
- 1.3.4. By End User
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Immunotherapy Drugs Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Immunotherapy Drugs Market Dynamics

3.1. Market Drivers
- 3.1.1. Technological advancements in antibody engineering
- 3.1.2. Rising demand for antibody therapies in clinical cancer treatment
- 3.1.3. Increasing need for personalized medicines and targeted therapies
3.2. Market Challenges
- 3.2.1. Stringent regulatory approval process
- 3.2.2. Complexities in development of antibody therapeutics
3.3. Market Opportunities
- 3.3.1. Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutions
- 3.3.2. Expansion of immunotherapy applications in different therapeutic areas
- 3.3.3. Growth of immunotherapy research in emerging markets

Chapter 4. Global Immunotherapy Drugs Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top Investment Opportunity
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Immunotherapy Drugs Market Size & Forecasts by Type 2022-2032

5.1. Segment Dashboard
5.2. Global Immunotherapy Drugs Market: Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Antibody Drugs
- 5.2.2. Inhibitor Drugs
- 5.2.3. Interferons and Interleukins
- 5.2.4. Cancer Vaccines
- 5.2.5. Other Types

Chapter 6. Global Immunotherapy Drugs Market Size & Forecasts by Application 2022-2032

6.1. Segment Dashboard
6.2. Global Immunotherapy Drugs Market: Application Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Cancer
- 6.2.2. Autoimmune and Inflammatory Diseases
- 6.2.3. Hematology
- 6.2.4. Osteology
- 6.2.5. Neurology
- 6.2.6. Other Applications

Chapter 7. Global Immunotherapy Drugs Market Size & Forecasts by Route of Administration 2022-2032

7.1. Segment Dashboard
7.2. Global Immunotherapy Drugs Market: Route of Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Intravenous
- 7.2.2. Subcutaneous
- 7.2.3. Other Routes of Administration

Chapter 8. Global Immunotherapy Drugs Market Size & Forecasts by End User 2022-2032

8.1. Segment Dashboard
8.2. Global Immunotherapy Drugs Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Hospitals
- 8.2.2. Long-Term Care Facilities
- 8.2.3. Other End Users

Chapter 9. Global Immunotherapy Drugs Market Size & Forecasts by Region 2022-2032

9.1. North America Immunotherapy Drugs Market
- 9.1.1. U.S. Immunotherapy Drugs Market
  - 9.1.1.1. Type breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Application breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Route of Administration breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End User breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Immunotherapy Drugs Market
9.2. Europe Immunotherapy Drugs Market
- 9.2.1. U.K. Immunotherapy Drugs Market
- 9.2.2. Germany Immunotherapy Drugs Market
- 9.2.3. France Immunotherapy Drugs Market
- 9.2.4. Spain Immunotherapy Drugs Market
- 9.2.5. Italy Immunotherapy Drugs Market
- 9.2.6. Rest of Europe Immunotherapy Drugs Market
9.3. Asia-Pacific Immunotherapy Drugs Market
- 9.3.1. China Immunotherapy Drugs Market
- 9.3.2. India Immunotherapy Drugs Market
- 9.3.3. Japan Immunotherapy Drugs Market
- 9.3.4. Australia Immunotherapy Drugs Market
- 9.3.5. South Korea Immunotherapy Drugs Market
- 9.3.6. Rest of Asia Pacific Immunotherapy Drugs Market
9.4. Latin America Immunotherapy Drugs Market
- 9.4.1. Brazil Immunotherapy Drugs Market
- 9.4.2. Mexico Immunotherapy Drugs Market
- 9.4.3. Rest of Latin America Immunotherapy Drugs Market
9.5. Middle East & Africa Immunotherapy Drugs Market
- 9.5.1. Saudi Arabia Immunotherapy Drugs Market
- 9.5.2. South Africa Immunotherapy Drugs Market
- 9.5.3. Rest of Middle East & Africa Immunotherapy Drugs Market

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. Merck & Co., Inc.
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Johnson & Johnson Services, Inc.
- 10.3.3. F. Hoffman-La Roche Ltd.
- 10.3.4. Pfizer Inc.
- 10.3.5. AstraZeneca
- 10.3.6. Novartis AG
- 10.3.7. Amgen Inc.
- 10.3.8. Gilead Sciences, Inc.
- 10.3.9. Bristol-Myers Squibb Company
- 10.3.10. Eli Lilly and Company
- 10.3.11. Sanofi
- 10.3.12. Takeda Pharmaceutical Company Limited
- 10.3.13. Teva Pharmaceutical Industries Ltd
- 10.3.14. GSK PLC
- 10.3.15. Abbvie Inc.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes